Effects of Clopidogrel on Blood Pressure

Blood Pressure Clinical Trial

Official title:

Phase IV Study of the Effects of Clopidogrel on Soluble CD40 Ligand, Endothelial Function and Blood Pressure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01112137
• Other study ID #: NLN5031
• Status: Completed
• Phase: Phase 4
• First received: April 26, 2010
• Last updated: April 27, 2010
• Start date: January 2005
• Est. completion date: April 2010

Study information

• Verified date: April 2010
• Source: University of Cologne
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

Context: Soluble CD40 ligand (sCD40L) released from activated platelets induces inflammatory transformation of the vascular endothelium and is an independent predictor of cardiovascular events. Arterial hypertension is associated with platelet activation, increased sCD40L levels and endothelial dysfunction suggesting that inhibition of platelet-derived sCD40L release may improve endothelial function and lower blood pressure (BP).

Objective: To determine the effects of clopidogrel on sCD40L, endothelial function and BP.

Design: Randomized, controlled, investigator-blinded, parallel-group, 2-phase trial in patients with coronary artery disease and essential arterial hypertension and those without hypertension.

Intervention: Participants receive a single 600-mg clopidogrel loading dose (phase I) followed by a daily 75-mg clopidogrel maintenance dose over 28 days (phase II).

Outcome Measures: Primary outcome measure is the change in BP from baseline. Secondary outcome measures are changes in biomarkers of platelet and endothelial function and their correlation with BP.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: April 2010
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 45 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients with coronary artery disease (CAD) and a clinical presentation of stable angina pectoris or acute coronary syndrome who had undergone percutaneous coronary intervention (PCI) with stent implantation

• 5-year history of essential arterial hypertension with a systolic BP between 140 and 170 mmHg or no hypertension (systolic BP <140mg Hg and diastolic BP <90 mmHg)

• treatment with clopidogrel (75 mg per day) for 6 to 12 months after PCI

• continuous use of aspirin (100 mg per day)

• no change in drug therapy within 3 months prestudy

Exclusion Criteria:

• stent thrombosis or another ischemic cardiovascular event following PCI

• use of other antiplatelet drugs or anticoagulants within 3 months prestudy

• surgery within 3 months prestudy

• arrhythmia

• valvular heart disease

• hematologic disorder

• severe renal disorder

• severe hepatic disorder

• chronic inflammatory disorder

• autoimmune disorder

• acute or chronic infection

• active malignancy

• a body-mass index below 18.5 or above 40 kg/m2

• nonadherence to therapy

• nonattendance to control visits

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Blood Pressure
• Endothelial Function
• Platelet Function

Intervention

Drug:
• Clopidogrel

• Clopidogrel

• Clopidogrel

• Clopidogrel

Locations

Country	Name	City	State
Germany	University of Cologne	Cologne
Netherlands	St Antonius Hospital Nieuwegein	Nieuwegein

Sponsors (1)

Lead Sponsor	Collaborator
University of Cologne

Countries where clinical trial is conducted

Germany,  Netherlands, 

References & Publications (4)

Chen C, Chai H, Wang X, Jiang J, Jamaluddin MS, Liao D, Zhang Y, Wang H, Bharadwaj U, Zhang S, Li M, Lin P, Yao Q. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood. 2008 Oct 15;112(8):3205-16. doi: 10.1182/blood-2008-03-143479. Epub 2008 Jul 24. — View Citation

Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML; CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003 Mar 20;348(12):1104-11. — View Citation

Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M, Tschentscher P, Meinertz T, Böger R, Baldus S. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):1648-52. Epub 2006 May 4. — View Citation

Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998 Feb 5;391(6667):591-4. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	blood pressure			No
Secondary	markers of platelet and endothelial function			No